GLP-1 Receptor Agonists and SGLT2 Inhibitors: New Anti-aging Tools?

Overview

Journal Future Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 26

PMID 39589856

Authors

Gaetano Santulli

Pasquale Mone

Fahimeh Varzideh

Affiliations

Soon will be listed here.

References

Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C . Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacol Res. 2022; 187:106597. PMC: 9946774. DOI: 10.1016/j.phrs.2022.106597. View

Forzano I, Wilson S, Lombardi A, Jankauskas S, Kansakar U, Mone P . SGLT2 inhibitors: an evidence-based update on cardiovascular implications. Expert Opin Investig Drugs. 2023; 32(9):839-847. PMC: 10591907. DOI: 10.1080/13543784.2023.2263354. View

Mone P, Ciccarelli M, Jankauskas S, Guerra G, Vecchione C, Visco V . SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?. Lancet Healthy Longev. 2024; 5(9):100632. PMC: 11472278. DOI: 10.1016/j.lanhl.2024.08.001. View

Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F . Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022; 21(1):77. PMC: 9107763. DOI: 10.1186/s12933-022-01506-8. View

Mone P, Varzideh F, Jankauskas S, Pansini A, Lombardi A, Frullone S . SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. Hypertension. 2022; 79(8):1633-1643. PMC: 9642044. DOI: 10.1161/HYPERTENSIONAHA.122.19586. View

Le Couteur D, Barzilai N . New horizons in life extension, healthspan extension and exceptional longevity. Age Ageing. 2022; 51(8). PMC: 9356533. DOI: 10.1093/ageing/afac156. View

Forzano I, Varzideh F, Avvisato R, Jankauskas S, Mone P, Santulli G . Tirzepatide: A Systematic Update. Int J Mol Sci. 2022; 23(23). PMC: 9741068. DOI: 10.3390/ijms232314631. View

Mone P, Lombardi A, Kansakar U, Varzideh F, Jankauskas S, Pansini A . Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes. J Pharmacol Exp Ther. 2022; 384(1):116-122. PMC: 9827502. DOI: 10.1124/jpet.121.001251. View

Mone P, De Luca A, Santulli G . Editorial: Frailty and oxidative stress. Front Aging. 2024; 4:1345486. PMC: 10951105. DOI: 10.3389/fragi.2023.1345486. View

10.

Natale F, Luisi E, Franzese R, Mollo N, Solimene A, Caso V . Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population. J Cardiovasc Dev Dis. 2024; 11(5). PMC: 11122593. DOI: 10.3390/jcdd11050145. View

11.

Zhang S, Qi Z, Wang Y, Song D, Zhu D . Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023; 14:1203666. PMC: 10351980. DOI: 10.3389/fendo.2023.1203666. View

12.

Lambadiari V, Thymis J, Kouretas D, Skaperda Z, Tekos F, Kousathana F . Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes. Antioxidants (Basel). 2021; 10(9). PMC: 8468804. DOI: 10.3390/antiox10091379. View

13.

Gourdy P, Darmon P, Dievart F, Halimi J, Guerci B . Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023; 22(1):79. PMC: 10067319. DOI: 10.1186/s12933-023-01798-4. View

14.

Varzideh F, Kansakar U, Santulli G . SGLT2 inhibitors in cardiovascular medicine. Eur Heart J Cardiovasc Pharmacother. 2021; 7(4):e67-e68. PMC: 8488965. DOI: 10.1093/ehjcvp/pvab039. View

15.

Loria F, Mone P, Rispoli A, Di Fonzo R, Masarone D, Mancusi C . The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better. Cardiovasc Diabetol. 2024; 23(1):423. PMC: 11583416. DOI: 10.1186/s12933-024-02515-5. View

16.

Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E . Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract. 2014; 103(2):269-75. DOI: 10.1016/j.diabres.2014.01.010. View

17.

Santulli G, Varzideh F, Forzano I, Wilson S, Salemme L, de Donato A . Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart. Hypertension. 2023; 80(9):1800-1809. PMC: 10529735. DOI: 10.1161/HYPERTENSIONAHA.123.20598. View

18.

Bantounou M, Sardellis P, Plascevic J, Awaes-Mahmood R, Kaczmarek J, Black Boada D . Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes. ESC Heart Fail. 2024; . DOI: 10.1002/ehf2.15036. View

19.

Santulli G . Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. N Engl J Med. 2022; 386(7):e17. PMC: 8941980. DOI: 10.1056/NEJMc2114590. View

20.

Kopp K, Glotfelty E, Li Y, Greig N . Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol Res. 2022; 186:106550. PMC: 9712272. DOI: 10.1016/j.phrs.2022.106550. View